September 5, 2007Open Access

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

RCB determined from routine pathologic materials represented the distribution of RD, was a significant predictor of DRFS, and can be used to define categories of near-complete response and chemotherapy resistance.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Symmans et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8e8a62c39562886ae3260 https://doi.org/https://doi.org/10.1200/jco.2007.10.6823

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma2006 · 114 citations
2Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.1998 · 2,192 citations
3Surrogate Endpoints And FDA’s Accelerated Approval Process2005 · 248 citations
4Pathological assessment of response to induction chemotherapy in breast cancer.1986 · 341 citations
5Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.1995 · 431 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo